Summary

The global Anti-CD133 Antibody market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Anti-CD133 Antibody is an antibody that specifically binds to CD133, a cell surface protein known as cluster of differentiation 133. CD133 is primarily found on stem cells, including those of the blood and epithelial tissues. This antibody is widely used in research to isolate and study stem cells, particularly in the context of cancer research, where CD133 has been associated with tumor initiating cells. It is also explored for its potential in regenerative medicine and tissue engineering due to CD133"s presence on cells with regenerative potential.
The industry trend for Anti-CD133 Antibody has seen a rise as it becomes an increasingly important tool in stem cell research and oncology. The antibody"s role in identifying and isolating cancer stem cells has implications for the development of novel therapeutics targeting these cells, which are believed to be responsible for tumor recurrence and resistance to treatment. Additionally, the potential for CD133 in regenerative applications is driving the demand for high-quality Anti-CD133 Antibody products. As research progresses and the functions of CD133 in various diseases are further understood, the industry trend for this antibody is expected to continue growing.
The global Anti-CD133 Antibody market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
BosterBio
GeneTex
ProSci
Bioss
Absolute Antibody
MyBioSource
Biorbyt
Thermo Fisher Scientific
R&D Systems
Novus Biologicals
BioLegend
G Biosciences
Cell Signaling Technology
RayBiotech
HUABIO
Abeomics
Proteintech Group
Miltenyi Biotec
Wuhan Fine Biotech
NSJ Bioreagents
Bethyl Laboratories
OriGene Technologies
Signalway Antibody
Abnova
Bioassay Technology Laboratory
AAT Bioquest
Sino Biological
ProteoGenix
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Anti-CD133 Antibody market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Anti-CD133 Antibody value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-CD133 Antibody Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Anti-CD133 Antibody Market Share by Revenue, by Region (2021-2026)
2.4 Global Anti-CD133 Antibody Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Anti-CD133 Antibody Market Size and Prospective (2021-2032)
2.5.2 Europe Anti-CD133 Antibody Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Anti-CD133 Antibody Market Size and Prospective (2021-2032)
2.5.4 Latin America Anti-CD133 Antibody Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Anti-CD133 Antibody Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Anti-CD133 Antibody Historical Market Size by Type (2021-2026)
3.2 Global Anti-CD133 Antibody Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Anti-CD133 Antibody
4 Breakdown Data by Application
4.1 Global Anti-CD133 Antibody Historical Market Size by Application (2021-2026)
4.2 Global Anti-CD133 Antibody Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Anti-CD133 Antibody Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Anti-CD133 Antibody Players by Revenue (2021-2026)
5.1.2 Global Anti-CD133 Antibody Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Anti-CD133 Antibody Revenue
5.4 Global Anti-CD133 Antibody Market Concentration Analysis
5.4.1 Global Anti-CD133 Antibody Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Anti-CD133 Antibody Revenue in 2025
5.5 Global Key Players of Anti-CD133 Antibody Head Offices and Areas Served
5.6 Global Key Players of Anti-CD133 Antibody, Product and Application
5.7 Global Key Players of Anti-CD133 Antibody, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Anti-CD133 Antibody Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Anti-CD133 Antibody Market Size by Type (2021-2026)
6.1.2.2 North America Anti-CD133 Antibody Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Anti-CD133 Antibody Market Size by Application (2021-2026)
6.1.3.2 North America Anti-CD133 Antibody Market Share by Application (2021-2026)
6.1.4 North America Anti-CD133 Antibody Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Anti-CD133 Antibody Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Anti-CD133 Antibody Market Size by Type (2021-2026)
6.2.2.2 Europe Anti-CD133 Antibody Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Anti-CD133 Antibody Market Size by Application (2021-2026)
6.2.3.2 Europe Anti-CD133 Antibody Market Share by Application (2021-2026)
6.2.4 Europe Anti-CD133 Antibody Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Anti-CD133 Antibody Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Anti-CD133 Antibody Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Anti-CD133 Antibody Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Anti-CD133 Antibody Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Anti-CD133 Antibody Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Anti-CD133 Antibody Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Anti-CD133 Antibody Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Anti-CD133 Antibody Market Size by Type (2021-2026)
6.4.2.2 Latin America Anti-CD133 Antibody Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Anti-CD133 Antibody Market Size by Application (2021-2026)
6.4.3.2 Latin America Anti-CD133 Antibody Market Share by Application (2021-2026)
6.4.4 Latin America Anti-CD133 Antibody Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Anti-CD133 Antibody Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Anti-CD133 Antibody Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Anti-CD133 Antibody Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Anti-CD133 Antibody Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Anti-CD133 Antibody Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Anti-CD133 Antibody Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 BosterBio
7.1.1 BosterBio Company Details
7.1.2 BosterBio Business Overview
7.1.3 BosterBio Anti-CD133 Antibody Introduction
7.1.4 BosterBio Revenue in Anti-CD133 Antibody Business (2021-2026)
7.1.5 BosterBio Recent Development
7.2 GeneTex
7.2.1 GeneTex Company Details
7.2.2 GeneTex Business Overview
7.2.3 GeneTex Anti-CD133 Antibody Introduction
7.2.4 GeneTex Revenue in Anti-CD133 Antibody Business (2021-2026)
7.2.5 GeneTex Recent Development
7.3 ProSci
7.3.1 ProSci Company Details
7.3.2 ProSci Business Overview
7.3.3 ProSci Anti-CD133 Antibody Introduction
7.3.4 ProSci Revenue in Anti-CD133 Antibody Business (2021-2026)
7.3.5 ProSci Recent Development
7.4 Bioss
7.4.1 Bioss Company Details
7.4.2 Bioss Business Overview
7.4.3 Bioss Anti-CD133 Antibody Introduction
7.4.4 Bioss Revenue in Anti-CD133 Antibody Business (2021-2026)
7.4.5 Bioss Recent Development
7.5 Absolute Antibody
7.5.1 Absolute Antibody Company Details
7.5.2 Absolute Antibody Business Overview
7.5.3 Absolute Antibody Anti-CD133 Antibody Introduction
7.5.4 Absolute Antibody Revenue in Anti-CD133 Antibody Business (2021-2026)
7.5.5 Absolute Antibody Recent Development
7.6 MyBioSource
7.6.1 MyBioSource Company Details
7.6.2 MyBioSource Business Overview
7.6.3 MyBioSource Anti-CD133 Antibody Introduction
7.6.4 MyBioSource Revenue in Anti-CD133 Antibody Business (2021-2026)
7.6.5 MyBioSource Recent Development
7.7 Biorbyt
7.7.1 Biorbyt Company Details
7.7.2 Biorbyt Business Overview
7.7.3 Biorbyt Anti-CD133 Antibody Introduction
7.7.4 Biorbyt Revenue in Anti-CD133 Antibody Business (2021-2026)
7.7.5 Biorbyt Recent Development
7.8 Thermo Fisher Scientific
7.8.1 Thermo Fisher Scientific Company Details
7.8.2 Thermo Fisher Scientific Business Overview
7.8.3 Thermo Fisher Scientific Anti-CD133 Antibody Introduction
7.8.4 Thermo Fisher Scientific Revenue in Anti-CD133 Antibody Business (2021-2026)
7.8.5 Thermo Fisher Scientific Recent Development
7.9 R&D Systems
7.9.1 R&D Systems Company Details
7.9.2 R&D Systems Business Overview
7.9.3 R&D Systems Anti-CD133 Antibody Introduction
7.9.4 R&D Systems Revenue in Anti-CD133 Antibody Business (2021-2026)
7.9.5 R&D Systems Recent Development
7.10 Novus Biologicals
7.10.1 Novus Biologicals Company Details
7.10.2 Novus Biologicals Business Overview
7.10.3 Novus Biologicals Anti-CD133 Antibody Introduction
7.10.4 Novus Biologicals Revenue in Anti-CD133 Antibody Business (2021-2026)
7.10.5 Novus Biologicals Recent Development
7.11 BioLegend
7.11.1 BioLegend Company Details
7.11.2 BioLegend Business Overview
7.11.3 BioLegend Anti-CD133 Antibody Introduction
7.11.4 BioLegend Revenue in Anti-CD133 Antibody Business (2021-2026)
7.11.5 BioLegend Recent Development
7.12 G Biosciences
7.12.1 G Biosciences Company Details
7.12.2 G Biosciences Business Overview
7.12.3 G Biosciences Anti-CD133 Antibody Introduction
7.12.4 G Biosciences Revenue in Anti-CD133 Antibody Business (2021-2026)
7.12.5 G Biosciences Recent Development
7.13 Cell Signaling Technology
7.13.1 Cell Signaling Technology Company Details
7.13.2 Cell Signaling Technology Business Overview
7.13.3 Cell Signaling Technology Anti-CD133 Antibody Introduction
7.13.4 Cell Signaling Technology Revenue in Anti-CD133 Antibody Business (2021-2026)
7.13.5 Cell Signaling Technology Recent Development
7.14 RayBiotech
7.14.1 RayBiotech Company Details
7.14.2 RayBiotech Business Overview
7.14.3 RayBiotech Anti-CD133 Antibody Introduction
7.14.4 RayBiotech Revenue in Anti-CD133 Antibody Business (2021-2026)
7.14.5 RayBiotech Recent Development
7.15 HUABIO
7.15.1 HUABIO Company Details
7.15.2 HUABIO Business Overview
7.15.3 HUABIO Anti-CD133 Antibody Introduction
7.15.4 HUABIO Revenue in Anti-CD133 Antibody Business (2021-2026)
7.15.5 HUABIO Recent Development
7.16 Abeomics
7.16.1 Abeomics Company Details
7.16.2 Abeomics Business Overview
7.16.3 Abeomics Anti-CD133 Antibody Introduction
7.16.4 Abeomics Revenue in Anti-CD133 Antibody Business (2021-2026)
7.16.5 Abeomics Recent Development
7.17 Proteintech Group
7.17.1 Proteintech Group Company Details
7.17.2 Proteintech Group Business Overview
7.17.3 Proteintech Group Anti-CD133 Antibody Introduction
7.17.4 Proteintech Group Revenue in Anti-CD133 Antibody Business (2021-2026)
7.17.5 Proteintech Group Recent Development
7.18 Miltenyi Biotec
7.18.1 Miltenyi Biotec Company Details
7.18.2 Miltenyi Biotec Business Overview
7.18.3 Miltenyi Biotec Anti-CD133 Antibody Introduction
7.18.4 Miltenyi Biotec Revenue in Anti-CD133 Antibody Business (2021-2026)
7.18.5 Miltenyi Biotec Recent Development
7.19 Wuhan Fine Biotech
7.19.1 Wuhan Fine Biotech Company Details
7.19.2 Wuhan Fine Biotech Business Overview
7.19.3 Wuhan Fine Biotech Anti-CD133 Antibody Introduction
7.19.4 Wuhan Fine Biotech Revenue in Anti-CD133 Antibody Business (2021-2026)
7.19.5 Wuhan Fine Biotech Recent Development
7.20 NSJ Bioreagents
7.20.1 NSJ Bioreagents Company Details
7.20.2 NSJ Bioreagents Business Overview
7.20.3 NSJ Bioreagents Anti-CD133 Antibody Introduction
7.20.4 NSJ Bioreagents Revenue in Anti-CD133 Antibody Business (2021-2026)
7.20.5 NSJ Bioreagents Recent Development
7.21 Bethyl Laboratories
7.21.1 Bethyl Laboratories Company Details
7.21.2 Bethyl Laboratories Business Overview
7.21.3 Bethyl Laboratories Anti-CD133 Antibody Introduction
7.21.4 Bethyl Laboratories Revenue in Anti-CD133 Antibody Business (2021-2026)
7.21.5 Bethyl Laboratories Recent Development
7.22 OriGene Technologies
7.22.1 OriGene Technologies Company Details
7.22.2 OriGene Technologies Business Overview
7.22.3 OriGene Technologies Anti-CD133 Antibody Introduction
7.22.4 OriGene Technologies Revenue in Anti-CD133 Antibody Business (2021-2026)
7.22.5 OriGene Technologies Recent Development
7.23 Signalway Antibody
7.23.1 Signalway Antibody Company Details
7.23.2 Signalway Antibody Business Overview
7.23.3 Signalway Antibody Anti-CD133 Antibody Introduction
7.23.4 Signalway Antibody Revenue in Anti-CD133 Antibody Business (2021-2026)
7.23.5 Signalway Antibody Recent Development
7.24 Abnova
7.24.1 Abnova Company Details
7.24.2 Abnova Business Overview
7.24.3 Abnova Anti-CD133 Antibody Introduction
7.24.4 Abnova Revenue in Anti-CD133 Antibody Business (2021-2026)
7.24.5 Abnova Recent Development
7.25 Bioassay Technology Laboratory
7.25.1 Bioassay Technology Laboratory Company Details
7.25.2 Bioassay Technology Laboratory Business Overview
7.25.3 Bioassay Technology Laboratory Anti-CD133 Antibody Introduction
7.25.4 Bioassay Technology Laboratory Revenue in Anti-CD133 Antibody Business (2021-2026)
7.25.5 Bioassay Technology Laboratory Recent Development
7.26 AAT Bioquest
7.26.1 AAT Bioquest Company Details
7.26.2 AAT Bioquest Business Overview
7.26.3 AAT Bioquest Anti-CD133 Antibody Introduction
7.26.4 AAT Bioquest Revenue in Anti-CD133 Antibody Business (2021-2026)
7.26.5 AAT Bioquest Recent Development
7.27 Sino Biological
7.27.1 Sino Biological Company Details
7.27.2 Sino Biological Business Overview
7.27.3 Sino Biological Anti-CD133 Antibody Introduction
7.27.4 Sino Biological Revenue in Anti-CD133 Antibody Business (2021-2026)
7.27.5 Sino Biological Recent Development
7.28 ProteoGenix
7.28.1 ProteoGenix Company Details
7.28.2 ProteoGenix Business Overview
7.28.3 ProteoGenix Anti-CD133 Antibody Introduction
7.28.4 ProteoGenix Revenue in Anti-CD133 Antibody Business (2021-2026)
7.28.5 ProteoGenix Recent Development
8 Anti-CD133 Antibody Market Dynamics
8.1 Anti-CD133 Antibody Industry Trends
8.2 Anti-CD133 Antibody Market Drivers
8.3 Anti-CD133 Antibody Market Challenges
8.4 Anti-CD133 Antibody Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Anti-CD133 Antibody Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Anti-CD133 Antibody Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Anti-CD133 Antibody Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Anti-CD133 Antibody Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Anti-CD133 Antibody Revenue Share by Region (2021-2026)
Table 6. Global Anti-CD133 Antibody Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Anti-CD133 Antibody Revenue Share Forecast by Region (2027-2032)
Table 8. Global Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Anti-CD133 Antibody Market Share by Revenue, by Type (2021-2026)
Table 10. Global Anti-CD133 Antibody Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Anti-CD133 Antibody Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Anti-CD133 Antibody Market Share by Revenue, by Application (2021-2026)
Table 15. Global Anti-CD133 Antibody Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Anti-CD133 Antibody Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Anti-CD133 Antibody Applications
Table 18. Global Anti-CD133 Antibody Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Anti-CD133 Antibody Market Share by Players (2021-2026)
Table 20. Global Top Anti-CD133 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD133 Antibody as of 2025)
Table 21. Ranking of Global Top Anti-CD133 Antibody Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Anti-CD133 Antibody Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Anti-CD133 Antibody, Headquarters and Area Served
Table 24. Global Key Players of Anti-CD133 Antibody, Product and Application
Table 25. Global Key Players of Anti-CD133 Antibody, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Anti-CD133 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Anti-CD133 Antibody Market Share by Revenue, by Company (2021-2026)
Table 29. North America Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Anti-CD133 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Anti-CD133 Antibody Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Anti-CD133 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Anti-CD133 Antibody Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Anti-CD133 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Anti-CD133 Antibody Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Anti-CD133 Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Anti-CD133 Antibody Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Anti-CD133 Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Anti-CD133 Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 47. BosterBio Company Details
Table 48. BosterBio Business Overview
Table 49. BosterBio Anti-CD133 Antibody Product
Table 50. BosterBio Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 51. BosterBio Recent Development
Table 52. GeneTex Company Details
Table 53. GeneTex Business Overview
Table 54. GeneTex Anti-CD133 Antibody Product
Table 55. GeneTex Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 56. GeneTex Recent Development
Table 57. ProSci Company Details
Table 58. ProSci Business Overview
Table 59. ProSci Anti-CD133 Antibody Product
Table 60. ProSci Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 61. ProSci Recent Development
Table 62. Bioss Company Details
Table 63. Bioss Business Overview
Table 64. Bioss Anti-CD133 Antibody Product
Table 65. Bioss Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 66. Bioss Recent Development
Table 67. Absolute Antibody Company Details
Table 68. Absolute Antibody Business Overview
Table 69. Absolute Antibody Anti-CD133 Antibody Product
Table 70. Absolute Antibody Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 71. Absolute Antibody Recent Development
Table 72. MyBioSource Company Details
Table 73. MyBioSource Business Overview
Table 74. MyBioSource Anti-CD133 Antibody Product
Table 75. MyBioSource Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 76. MyBioSource Recent Development
Table 77. Biorbyt Company Details
Table 78. Biorbyt Business Overview
Table 79. Biorbyt Anti-CD133 Antibody Product
Table 80. Biorbyt Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 81. Biorbyt Recent Development
Table 82. Thermo Fisher Scientific Company Details
Table 83. Thermo Fisher Scientific Business Overview
Table 84. Thermo Fisher Scientific Anti-CD133 Antibody Product
Table 85. Thermo Fisher Scientific Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 86. Thermo Fisher Scientific Recent Development
Table 87. R&D Systems Company Details
Table 88. R&D Systems Business Overview
Table 89. R&D Systems Anti-CD133 Antibody Product
Table 90. R&D Systems Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 91. R&D Systems Recent Development
Table 92. Novus Biologicals Company Details
Table 93. Novus Biologicals Business Overview
Table 94. Novus Biologicals Anti-CD133 Antibody Product
Table 95. Novus Biologicals Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 96. Novus Biologicals Recent Development
Table 97. BioLegend Company Details
Table 98. BioLegend Business Overview
Table 99. BioLegend Anti-CD133 Antibody Product
Table 100. BioLegend Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 101. BioLegend Recent Development
Table 102. G Biosciences Company Details
Table 103. G Biosciences Business Overview
Table 104. G Biosciences Anti-CD133 Antibody Product
Table 105. G Biosciences Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 106. G Biosciences Recent Development
Table 107. Cell Signaling Technology Company Details
Table 108. Cell Signaling Technology Business Overview
Table 109. Cell Signaling Technology Anti-CD133 Antibody Product
Table 110. Cell Signaling Technology Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 111. Cell Signaling Technology Recent Development
Table 112. RayBiotech Company Details
Table 113. RayBiotech Business Overview
Table 114. RayBiotech Anti-CD133 Antibody Product
Table 115. RayBiotech Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 116. RayBiotech Recent Development
Table 117. HUABIO Company Details
Table 118. HUABIO Business Overview
Table 119. HUABIO Anti-CD133 Antibody Product
Table 120. HUABIO Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 121. HUABIO Recent Development
Table 122. Abeomics Company Details
Table 123. Abeomics Business Overview
Table 124. Abeomics Anti-CD133 Antibody Product
Table 125. Abeomics Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 126. Abeomics Recent Development
Table 127. Proteintech Group Company Details
Table 128. Proteintech Group Business Overview
Table 129. Proteintech Group Anti-CD133 Antibody Product
Table 130. Proteintech Group Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 131. Proteintech Group Recent Development
Table 132. Miltenyi Biotec Company Details
Table 133. Miltenyi Biotec Business Overview
Table 134. Miltenyi Biotec Anti-CD133 Antibody Product
Table 135. Miltenyi Biotec Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 136. Miltenyi Biotec Recent Development
Table 137. Wuhan Fine Biotech Company Details
Table 138. Wuhan Fine Biotech Business Overview
Table 139. Wuhan Fine Biotech Anti-CD133 Antibody Product
Table 140. Wuhan Fine Biotech Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 141. Wuhan Fine Biotech Recent Development
Table 142. NSJ Bioreagents Company Details
Table 143. NSJ Bioreagents Business Overview
Table 144. NSJ Bioreagents Anti-CD133 Antibody Product
Table 145. NSJ Bioreagents Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 146. NSJ Bioreagents Recent Development
Table 147. Bethyl Laboratories Company Details
Table 148. Bethyl Laboratories Business Overview
Table 149. Bethyl Laboratories Anti-CD133 Antibody Product
Table 150. Bethyl Laboratories Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 151. Bethyl Laboratories Recent Development
Table 152. OriGene Technologies Company Details
Table 153. OriGene Technologies Business Overview
Table 154. OriGene Technologies Anti-CD133 Antibody Product
Table 155. OriGene Technologies Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 156. OriGene Technologies Recent Development
Table 157. Signalway Antibody Company Details
Table 158. Signalway Antibody Business Overview
Table 159. Signalway Antibody Anti-CD133 Antibody Product
Table 160. Signalway Antibody Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 161. Signalway Antibody Recent Development
Table 162. Abnova Company Details
Table 163. Abnova Business Overview
Table 164. Abnova Anti-CD133 Antibody Product
Table 165. Abnova Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 166. Abnova Recent Development
Table 167. Bioassay Technology Laboratory Company Details
Table 168. Bioassay Technology Laboratory Business Overview
Table 169. Bioassay Technology Laboratory Anti-CD133 Antibody Product
Table 170. Bioassay Technology Laboratory Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 171. Bioassay Technology Laboratory Recent Development
Table 172. AAT Bioquest Company Details
Table 173. AAT Bioquest Business Overview
Table 174. AAT Bioquest Anti-CD133 Antibody Product
Table 175. AAT Bioquest Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 176. AAT Bioquest Recent Development
Table 177. Sino Biological Company Details
Table 178. Sino Biological Business Overview
Table 179. Sino Biological Anti-CD133 Antibody Product
Table 180. Sino Biological Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 181. Sino Biological Recent Development
Table 182. ProteoGenix Company Details
Table 183. ProteoGenix Business Overview
Table 184. ProteoGenix Anti-CD133 Antibody Product
Table 185. ProteoGenix Revenue in Anti-CD133 Antibody Business (2021-2026) & (US$ Million)
Table 186. ProteoGenix Recent Development
Table 187. Anti-CD133 Antibody Market Trends
Table 188. Anti-CD133 Antibody Market Drivers
Table 189. Anti-CD133 Antibody Market Challenges
Table 190. Anti-CD133 Antibody Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources


List of Figures
Figure 1. Anti-CD133 Antibody Product Picture
Figure 2. Global Anti-CD133 Antibody Market Share by Type: 2025 vs 2032
Figure 3. Monoclonal Antibody Features
Figure 4. Polyclonal Antibody Features
Figure 5. Global Anti-CD133 Antibody Market Share by Application: 2025 vs 2032
Figure 6. Biotechnology
Figure 7. Medical
Figure 8. University
Figure 9. Others
Figure 10. Anti-CD133 Antibody Report Years Considered
Figure 11. Global Anti-CD133 Antibody Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 12. Global Anti-CD133 Antibody Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Anti-CD133 Antibody Market Share by Revenue, by Region: 2021 vs 2025
Figure 14. North America Anti-CD133 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 15. Europe Anti-CD133 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Asia-Pacific Anti-CD133 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Latin America Anti-CD133 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Middle East & Africa Anti-CD133 Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Global Anti-CD133 Antibody Market Share by Players in 2025
Figure 20. Global Top Anti-CD133 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD133 Antibody as of 2025)
Figure 21. The Top 10 and 5 Players Market Share by Anti-CD133 Antibody Revenue in 2025
Figure 22. North America Anti-CD133 Antibody Market Share by Type (2021-2026)
Figure 23. North America Anti-CD133 Antibody Market Share by Application (2021-2026)
Figure 24. Europe Anti-CD133 Antibody Market Share by Type (2021-2026)
Figure 25. Europe Anti-CD133 Antibody Market Share by Application (2021-2026)
Figure 26. Asia-Pacific Anti-CD133 Antibody Market Share by Type (2021-2026)
Figure 27. Asia-Pacific Anti-CD133 Antibody Market Share by Application (2021-2026)
Figure 28. Latin America Anti-CD133 Antibody Market Share by Type (2021-2026)
Figure 29. Latin America Anti-CD133 Antibody Market Share by Application (2021-2026)
Figure 30. Middle East & Africa Anti-CD133 Antibody Market Share by Type (2021-2026)
Figure 31. Middle East & Africa Anti-CD133 Antibody Market Share by Application (2021-2026)
Figure 32. BosterBio Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 33. GeneTex Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 34. ProSci Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 35. Bioss Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 36. Absolute Antibody Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 37. MyBioSource Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 38. Biorbyt Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 39. Thermo Fisher Scientific Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 40. R&D Systems Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 41. Novus Biologicals Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 42. BioLegend Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 43. G Biosciences Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 44. Cell Signaling Technology Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 45. RayBiotech Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 46. HUABIO Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 47. Abeomics Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 48. Proteintech Group Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 49. Miltenyi Biotec Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 50. Wuhan Fine Biotech Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 51. NSJ Bioreagents Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 52. Bethyl Laboratories Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 53. OriGene Technologies Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 54. Signalway Antibody Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 55. Abnova Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 56. Bioassay Technology Laboratory Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 57. AAT Bioquest Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 58. Sino Biological Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 59. ProteoGenix Revenue Growth Rate in Anti-CD133 Antibody Business (2021-2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed